The U.S. Food and Drug Administration today approved Isembyld (apitegromab-mstn) injection to treat spinal muscular atrophy (SMA) in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment. Isembyld is the first therapy approved for SMA that directly targets muscle loss, working alongside existing treatments to address a critical dimension of the disease.